These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23425265)

  • 1. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 2. European perspective on biosimilars.
    Wadhwa M; Thorpe R
    Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
    [No Abstract]   [Full Text] [Related]  

  • 3. A wide angle view of biosimilars from a bioanalytical perspective.
    Oldfield P
    Bioanalysis; 2013 Mar; 5(5):533-5. PubMed ID: 23425269
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonclinical development of a biosimilar: the current landscape.
    O'Connor A; Rogge M
    Bioanalysis; 2013 Mar; 5(5):537-44. PubMed ID: 23425270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical development of biosimilars: an evolving landscape.
    Subramanyam M
    Bioanalysis; 2013 Mar; 5(5):575-86. PubMed ID: 23425273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in bioanalytical assays for biosimilars.
    Wang X; Chen L
    Bioanalysis; 2014 Aug; 6(16):2111-3. PubMed ID: 25331854
    [No Abstract]   [Full Text] [Related]  

  • 8. Conference Report: Bioanalysis-related topics presented at the International Conference and Exhibition on Biowaivers and Biosimilars.
    Colletti KS
    Bioanalysis; 2013 Mar; 5(5):529-31. PubMed ID: 23425268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics).
    Oldfield P
    Bioanalysis; 2011 Jul; 3(14):1551-3. PubMed ID: 21756087
    [No Abstract]   [Full Text] [Related]  

  • 10. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
    Ryding J; Stahl M; Ullmann M
    Bioanalysis; 2017 Sep; 9(18):1395-1406. PubMed ID: 28920451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

  • 15. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-Based Approach for Analytical Comparability and Comparability Protocols.
    Iyer KR; Lequeux I
    PDA J Pharm Sci Technol; 2020; 74(5):563-570. PubMed ID: 32295861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quotient Bioresearch complete £1.5 million expansion of bioanalytical research facilities.
    King G
    Bioanalysis; 2012 Nov; 4(22):2666. PubMed ID: 23346559
    [No Abstract]   [Full Text] [Related]  

  • 19. The rise of the biosimilar.
    McCamish M; Woollett G
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):597-9. PubMed ID: 23234317
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.
    Chamberlain P
    Bioanalysis; 2013 Mar; 5(5):561-74. PubMed ID: 23425272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.